Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 185-191

  Wislez, Marie ^a,b   Antoine, Martine ^a,b   Baudrin, Laurence ^c   Poulot, Virginie ^b   Neuville, Agnes ^d   Pradere, Maryvonne ^e   Longchampt, Elisabeth ^f   Isaac Sibille, Sylvie ^g   Lebitasy, Marie Paule ^c   Cadranel, Jacques ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Intergroupe Francophone de Cancerologie Thoracique IFCT   (France)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e Service d'Anatomie et de Cytologie Pathologiques   (France)

^f FOCH HOSPITAL   (France)

^g CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

EGFR; EGFR inhibitors; Mucinous BAC; Non mucinous BAC; Ras

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; K RAS PROTEIN; THYROID TRANSCRIPTION FACTOR 1;

AGED; ARTICLE; CANCER CONTROL; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN TOXICITY;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 77950459714     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.05.021     Document Type: Article

References (41)

1. Breathnach O.S., Ishibe N., Williams J., Linnoila R.I., Caporaso N., Johnson B.E. Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung. Cancer 1999, 86(7):1165-1173.
2. Ebright M.I., Zakowski M.F., Martin J., Venkatraman E.S., Miller V.A., Bains M.S., et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002, 74(November (5)):1640-1646.
3. Garfield D., Cadranel J., Wislez M., Franklin W., Hirsch F. The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol 2006, 1:340-359.
4. Miller V.A., Hirsch F.R., Johnson D.H. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol 2005, 23(May 10 (14)):3288-3293.
5. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. Pathology and genetics: tumours of the lung, pleura, thymus and heart. World Health Organization classification of tumours pathology and genetics of tumors of the lung, pleura, thymus, and heart 2004, 9-124. IARC Press, Lyon. W.D. Travis, E. Brambilla, H.K. Muller-Hermelink, C.C. Harris (Eds.).
6. West H.L., Crowley J.J., Vance R.B., Franklin W.A., Livingston R.B., Dakhil S.R., et al. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol 2005, 16(July (7)):1076-1080.
7. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21(June 15 (12)):2237-2246.
8. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290(October 22 (16)):2149-2158.
9. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004, 22(March 15 (6)):1103-1109.
10. Miller V.A., Riely G.J., Zakowski M.F., Li A.R., Patel J.D., Heelan R.T., et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008, 26(March 20 (9)):1472-1478.
11. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A.C., Gumerlock P., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005, 23(July 5 (28)):6838-6845. [Epub].
12. Cadranel J., Quoix E., Debove P., Moro-Sibilot D., Brechot J.M., Souquet P.J., et al. IFCT0401 trial: phase II study of gefitinib administered as first-line treatment in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC): final results on efficacy and survival. J Clin Oncol 2007, 25(June 20 Suppl.). [abstr 7560].
13. Wislez M., Antoine M., Poulot V., Baudrin L., Beau-Faller M., Morere J., et al. IFCT0401-bio phase II trial: gefitinib administered as 1st-line in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC)-predictive biomarkers of efficacy and survival. J Clin Oncol 2008, 26(May 20 Suppl.). [abstr 8071].
14. Liebow A.A. Bronchiolo-alveolar carcinoma. Adv Intern Med 1960, 10:329-358.
15. Travis W.D., Garg K., Franklin W.A., Wistuba I.I., Sabloff B., Noguchi M., et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005, 23(May 10 (14)):3279-3287.
16. Hirsch F.R., Scagliotti G.V., Langer C.J., Varella-Garcia M., Franklin W.A. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003, 41(August (Suppl. 1)):S29-42.
17. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97(9):643-655.
18. Awaya H., Takeshima Y., Furonaka O., Kohno N., Inai K. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol 2005, 58(October (10)):1076-1080.
19. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(May 20 (21)):2129-2139.
20. Quinlan R. C4.5: programs for machine learning 1993, Morgan Kaufman Publishers.
21. Manning J.T., Spjut H.J., Tschen J.A. Bronchioloalveolar carcinoma: the significance of two histopathologic types. Cancer 1984, 54(3):525-534.
22. Clayton F. Bronchioloalveolar carcinomas. Cell types, patterns of growth, and prognostic correlates. Cancer 1986, 57(April 15 (8)):1555-1564.
23. Nakamura N., Miyagi E., Murata S., Kawaoi A., Katoh R. Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues. Mod Pathol 2002, 15(October (10)):1058-1067.
24. Bohinski R.J., Di Lauro R., Whitsett J.A. The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis. Mol Cell Biol 1994, 14(September (9)):5671-5681.
25. Bruno M.D., Bohinski R.J., Huelsman K.M., Whitsett J.A., Korfhagen T.R. Lung cell-specific expression of the murine surfactant protein A (SP-A) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1. J Biol Chem 1995, 270(March 24 (12)):6531-6536.
26. Kelly S.E., Bachurski C.J., Burhans M.S., Glasser S.W. Transcription of the lung-specific surfactant protein C gene is mediated by thyroid transcription factor 1. J Biol Chem 1996, 271(March 22 (12)):6881-6888.
27. Zhang L., Whitsett J.A., Stripp B.R. Regulation of Clara cell secretory protein gene transcription by thyroid transcription factor-1. Biochim Biophys Acta 1997, 1350(February 28 (3)):359-367.
28. Maeshima A.M., Omatsu M., Tsuta K., Asamura H., Matsuno Y. Immunohistochemical expression of TTF-1 in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneity. Pathol Int 2008, 58(January (1)):31-37.
29. Yatabe Y., Mitsudomi T., Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002, 26(June (6)):767-773.
30. Goldstein N.S., Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol 2001, 116(3):319-325.
31. Sakuma Y., Matsukuma S., Yoshihara M., Nakamura Y., Noda K., Nakayama H., et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007, 128(July (1)):100-108.
32. Tam I.Y., Chung L.P., Suen W.S., Wang E., Wong M.C., Ho K.K., et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006, 12(March 1 (5)):1647-1653.
33. Finberg K.E., Sequist L.V., Joshi V.A., Muzikansky A., Miller J.M., Han M., et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007, 9(July (3)):320-326.
34. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005, 23(4):857-865.
35. Motoi N., Szoke J., Riely G.J., Seshan V.E., Kris M.G., Rusch V.W., et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes. EGFR mutations and gene expression analysis. Am J Surg Pathol 2008, 32(6):810-827.
36. Yatabe Y., Kosaka T., Takahashi T., Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005, 29(May (5)):633-639.
37. Maeshima A., Sakamoto M., Hirohashi S. Mixed mucinous-type and non-mucinous-type adenocarcinoma of the lung: immunohistochemical examination and K-ras gene mutation. Virchows Arch 2002, 440(April 26 (6)):598-603. [Epub].
38. Albertine K.H., MacRitchie A.N., Young B.J., Cho S.C., Kullama L.K., Carlton D.P., et al. Altered vascular development in preterm lambs with chronic lung injury. Chest 1998, 114(1 Suppl.):6S-7S.
39. Furak J., Trojan I., Szoke T., Tiszlavicz L., Morvay Z., Eller J., et al. Bronchioloalveolar lung cancer: occurrence, surgical treatment and survival. Eur J Cardiothorac Surg 2003, 23(May (5)):818-823.
40. Lantuejoul S., Nicholson A.G., Sartori G., Piolat C., Danel C., Brabencova E., et al. Mucinous cells in type 1 pulmonary congenital cystic adenomatoid malformation as mucinous bronchioloalveolar carcinoma precursors. Am J Surg Pathol 2007, 31(June (6)):961-969.
41. Hirsch F.R., Varella-Garcia M., Bunn P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24(31):5034-5042.